How spleen removal surgery affects blood fats in people with cirrhosis
Follows blood fat levels for 2 years after spleen removal in cirrhosis.
Plain-language title generated from the registry record
Registry title: Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)
Key facts
- Where
- Yangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with liver cirrhosis, an enlarged spleen and hypersplenism who are having laparoscopic splenectomy. It follows their blood fats for 2 years.
- Age
- 18 to 80 years
- Sex
- Men and women can join.
- Disease stage
- Confirmed liver cirrhosis with an enlarged spleen and hypersplenism. Liver function must be Child-Pugh Class A or B.
- Earlier treatment
- People who took lipid-lowering drugs, hormones, or other drugs that affect blood lipids within 1 month before surgery cannot join.
Main reasons for not taking part
- Child-Pugh Class C liver cirrhosis
- Previous abdominal surgery that makes laparoscopic splenectomy unsafe
- Severe heart, lung or brain blood vessel problems, cancer, or primary blood disorders
- Familial hyperlipidemia, uncontrolled severe diabetes, thyroid problems, or nephrotic syndrome
- Pregnancy or breastfeeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07588373, who can take part
Where in China
- Clinical Medical College of Yangzhou UniversityYangzhou, ChinaContact: Guo-Qing Jiang, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Northern Jiangsu People's Hospital
- Trial code
- NCT07588373
- Record updated
- 14 May 2026
- Original description
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing laparoscopic splenectomy to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether laparoscopic splenectomy can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.Read full original descriptionShow less
A Prospective, Single-Center, Observational Cohort Study to Evaluate the Short-Term and Long-Term (2-Year) Effects of Laparoscopic Splenectomy on Lipid Profiles in Patients With Liver Cirrhosis, Splenomegaly and Hypersplenism
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing laparoscopic splenectomy to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether laparoscopic splenectomy can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.
Inclusion: Age 18-80 years, male or female; Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging); Splenomegaly and hypersplenism; Child-Pugh Class A or B liver function; Signed written informed consent; Ability to complete 24-month follow-up.
Exclusion: Previous abdominal surgery precluding safe laparoscopic splenectomy; Metabolic/endocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery; Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery; No history of portal hypertension bleeding (esophageal and gastric variceal bleeding ); Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders; Infections/inflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases; Child-Pugh Class C liver cirrhosis; Pregnancy or lactation; Poor compliance, inability to complete follow-up.